Comparison timestamp: 2025-05-07 06:33:00 UTC
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/chikungunya/hcp/vaccine/index.html
Live cdc.gov URL ↗: https://www.cdc.gov/chikungunya/hcp/vaccine/index.html
RestoredCDC URL: http://restoredcdc.org/www.cdc.gov/chikungunya/hcp/vaccine/index.html
Live cdc.gov URL ↗: https://www.cdc.gov/chikungunya/hcp/vaccine/index.html
Removed: Line removed from cdc.gov. Specific word removals are highlighted.
Added: Line added to cdc.gov. Specific word additions are highlighted.
Injected:
Line or disclaimer added by RestoredCDC.org.
Unchanged: Line unchanged.
Original site: www.cdc.gov/chikungunya/hcp/vaccine/index.html | RestoredCDC.org is an independent project, not affiliated with CDC or any federal entity. Visit CDC.gov for free official information. Due to archival on January 6, 2025, recent outbreak data is unavailable. Videos are not restored. Access data.restoredcdc.org for restored data. Use of this site implies acceptance of this disclaimer.[More]About Us Report Bug Compare ContentSkip directly to site content Skip directly to search Skip directly to On This PageAn official website of the United States governmentHere's how you knowOfficial websites use .govA .gov website belongs to an official government organization in the United States.Secure .gov websites use HTTPSA lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.Chikungunya VirusExplore TopicsSearchSearchClear InputFor Everyone* About* Causes and Spread* Prevention* Data and Maps* Illness Info* View allHealth Care Providers* Clinical Signs and Symptoms* Clinical Testing and Diagnosis* Treatment and Prevention* Vaccine Information* View allPublic Health* Chikungunya Virus Resources* Transmission* Mosquito Control* View allRelated Topics:Vector-Borne DiseasesView Allsearch close searchsearchChikungunya Virus Menu CloseChikungunya Virus MenusearchFor Everyone* About* Causes and Spread* Prevention* Data and Maps* Illness Info* View AllHealth Care Providers* Clinical Signs and Symptoms* Clinical Testing and Diagnosis* Treatment and Prevention* Vaccine Information* View AllPublic Health* Chikungunya Virus Resources* Transmission* Mosquito Control* View AllRelated Topics* Vector-Borne DiseasesView All Chikungunya VirusClinical Signs and Symptoms Clinical Testing and Diagnosis Treatment and Prevention Vaccine Information View AllMay 20, 2024March 3, 2025Chikungunya Vaccine Information for Healthcare ProvidersKey points* One chikungunya vaccine (manufactured by Valneva and called IXCHIQ) is available in the United States.* The vaccine is licensed for adults aged 18 years and older.* The vaccine should be considered for some travelers at higher risk of exposure to chikungunya virus or at increased risk of severe disease.Chikungunya vaccineA live attenuated chikungunya vaccine (manufactured by Valneva as IXCHIQ) is the only chikungunya vaccine currently licensed in the United States. This vaccine was approved by the Food and Drug Administration (FDA) in November 2023. The U.S. Advisory Committee on Immunization Practices (ACIP) approved recommendations for use of the vaccine in travelers and laboratory workers in February 2024.Vaccine administration, contraindications, and precautionsIXCHIQ is licensed for use in adults aged 18 years and older. It is administered intramuscularly as a single 0.5mL dose. There are currently no recommendations for a booster dose of vaccine.To minimize the risk of serious adverse events, healthcare providers should carefully observe the contraindications and consider the precautions about vaccination prior to vaccine administration.Contraindications* Immunocompromising condition (due to immunodeficiencies or immunosuppressive and immunomodulatory therapies)* History of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine.Precautions* Pregnancy+ Pregnant persons should avoid the risk for chikungunya virus infection, if possible.+ Pregnant women should avoid the risk for chikungunya virus infection, if possible.+ In general, vaccination should be deferred until after delivery. However, when the risk of infection is high and exposure cannot be avoided, a health care provider should discuss with a pregnant person the potential risks of chikungunya virus infection and the potential benefits and risks of vaccination so that vaccination can be considered.+ In general, vaccination should be deferred until after delivery. However, when the risk of infection is high and exposure cannot be avoided, a health care provider should discuss with a pregnant woman the potential risks of chikungunya virus infection and the potential benefits and risks of vaccination so that vaccination can be considered.+ If pregnant persons choose to be vaccinated, out of caution vaccination should generally be avoided during the 1st trimester (until 14 weeks gestation) and after the 36th week of gestation.+ If a pregnant woman chooses to be vaccinated, out of caution vaccination should generally be avoided during the 1st trimester (until 14 weeks gestation) and after the 36th week of gestation.* Breastfeeding+ Breastfeeding persons and their infants should avoid the risk for chikungunya virus infection, if possible.+ Breastfeeding women and their infants should avoid the risk for chikungunya virus infection, if possible.+ In the absence of data, breastfeeding is a precaution for vaccination. However, when the risk of infection is high (e.g., during an outbreak) and exposure cannot be avoided, a health care provider should discuss with a breastfeeding person the health benefits of breastfeeding for the infant, the risks of chikungunya virus infection, and the potential benefits and risks of vaccination, and offer the vaccine to the breastfeeding person.+ In the absence of data, breastfeeding is a precaution for vaccination. However, when the risk of infection is high (e.g., during an outbreak) and exposure cannot be avoided, a health care provider should discuss with a breastfeeding woman the health benefits of breastfeeding for the infant, the risks of chikungunya virus infection, and the potential benefits and risks of vaccination, and offer the vaccine to the breastfeeding woman.Vaccine immunogenicity and side effectsNoticeCDC is currently investigating five hospitalizations for cardiac or neurologic events following vaccination with IXCHIQ among people 65 years of age and older. This topic will be discussed at an upcoming meeting of the Advisory Committee on Immunization Practices (ACIP). Healthcare providers should discuss the benefits and risks of vaccination with individual travelers based on their age, destination, trip duration, and planned activities.Clinical trial results indicated that vaccination resulted in seroresponse rates ≥96% through at least 6 months after vaccination. Data are being gathered on responses over the longer term.Common adverse reactions following vaccination that occurred in >10% of vaccinated persons in clinical trials included tenderness, headache, fatigue, myalgia, arthralgia, fever, and nausea. IXCHIQ also caused severe or prolonged chikungunya-like adverse reactions in some persons.More information about IXCHIQ can be found in the IXCHIQ product information available at the FDA IXCHIQ web page.Healthcare providers are encouraged to report all adverse events that might be caused by vaccination to the CDC/FDA Vaccine Adverse Events Reporting System (VAERS) by submitting a report online or by using a PDF FormConsiderations for chikungunya vaccine for travelersAll travelers to countries or territories with risk of chikungunya virus transmission should take steps to avoid mosquito bites. The risk for chikungunya for most U.S. travelers is low. However, some travelers are at increased risk for infection or more severe disease. Factors to assess when considering use of chikungunya vaccine include the likelihood of exposure to chikungunya virus, a traveler's risk factors for severe disease outcomes, and traveler preferences.View LargerAvailable infographic describing factors to assess when considering chikungunya vaccine. Use the link below to download.Factors to assess when considering chikungunya vaccineFactors to assess when considering chikungunya vaccineInfographic describing factors to assess when considering chikungunya vaccine.DownloadChikungunya vaccine recommendations for travelersChikungunya vaccine is recommended for persons aged 18 years and older traveling to a country or territory where there is a chikungunya outbreak.Chikungunya vaccine also may be considered for the following persons traveling to a country or territory without an outbreak but with evidence of chikungunya virus transmission among humans within the last 5 years:* Persons aged >65 years, particularly those with underlying medical conditions, who are likely to have at least moderate exposure* to mosquitoes, OR* Persons staying for a cumulative period of 6 months or more.*Moderate exposure could include travelers who might have at least 2 weeks (cumulative) of exposure to mosquitoes in indoor or outdoor settings. It does not include travelers who might have limited exposure to mosquitoes (e.g., business travelers likely to be mainly in mosquito-protected indoor settings).Healthcare providers can use CDC's decision tree to help determine when chikungunya vaccination for travelers is appropriate.View LargerAvailable infographic with a decision tree for chikungunya vaccination for travelers. Use the link below to download.Chikungunya vaccination for U.S. travelers decision treeInfographic describing the decision tree to determine if chikungunya vaccine is recommended or may be considered for certain travelers.DownloadChikungunya vaccination for laboratory workersChikungunya virus transmission through the aerosol and percutaneous routes has been documented in the laboratory setting, and transmission through accidental mucosal exposure is possible. Laboratory work with chikungunya virus is generally restricted to biosafety level-3 (BSL-3) facilities and practices.Chikungunya vaccine is recommended for laboratory workers with potential for exposure to chikungunya virus.A local institutional biosafety committee should undertake a risk assessment of the potential for exposure to chikungunya virus for each laboratory worker working with the virus. The committee should consider the type of work to be performed and the biosafety level at which work will be conducted. Vaccination is not necessary for workers handling clinical samples who should routinely use standard practices for handling patient samples.On This Page* Chikungunya vaccine* Vaccine administration, contraindications, and precautions* Vaccine immunogenicity and side effects* Considerations for chikungunya vaccine for travelers* Chikungunya vaccine recommendations for travelers* Chikungunya vaccination for laboratory workersRelated PagesClinical Signs and SymptomsRelated Pages** Clinical Signs and Symptoms* Clinical Testing and Diagnosis* Treatment and Prevention*View All Chikungunya VirusMay 20, 2024Sources Print ShareFacebook LinkedIn Twitter SyndicateContent Source:National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)Related PagesClinical Signs and SymptomsRelated Pages** Clinical Signs and Symptoms* Clinical Testing and Diagnosis* Treatment and Prevention*View All Chikungunya VirusBack to TopChikungunya VirusChikungunya virus is primarily spread by mosquitoes. Learn about areas at risk, the illness it causes, and ways to prevent becoming infected, including vaccination.View AllFor Everyone* About* Causes and Spread* Prevention* Data and Maps* Illness InfoHealth Care Providers* Clinical Signs and Symptoms* Clinical Testing and Diagnosis* Treatment and Prevention* View AllPublic Health* Chikungunya Virus Resources* Transmission* Mosquito ControlSign up for Email UpdatesContact UsContact Us* Call 800-232-4636* Contact CDCAbout CDCAbout CDC* Pressroom* Organization* Budget & Funding* Careers & JobsPolicies* Accessibility* External Links* Privacy* Web Policies* FOIA* OIG* No Fear Act* Nondiscrimination* Vulnerability Disclosure PolicyLanguagesLanguages* EspañolLanguage Assistance* Español* 繁體中文* Tiếng Việt* 한국어* Tagalog* Русский* العربية* Kreyòl Ayisyen* Français* Polski* Português* Italiano* Deutsch* 日本語* فارسی* EnglishArchive* CDC Archive* Public Health PublicationsContact UsContact Us* Call 800-232-4636* Contact CDCAbout CDC* Pressroom* Organization* Budget & Funding* Careers & Jobs* About CDCPolicies* Accessibility* External Links* Privacy* Web Policies* FOIA* OIG* No Fear Act* Nondiscrimination* Vulnerability Disclosure PolicyLanguagesLanguages* EspañolLanguage Assistance* Español* 繁體中文* Tiếng Việt* 한국어* Tagalog* Русский* العربية* Kreyòl Ayisyen* Français* Polski* Português* Italiano* Deutsch* 日本語* فارسی* EnglishArchive* CDC Archive* Public Health PublicationsHHS.gov USA.gov
Note: Comparison ignores leading/trailing whitespace
and certain script/tracking codes. Word-level
highlighting (optional above) only applies to changed
lines.